Loading cancer entity…
Loading cancer entity…
Clinical trials
79 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04710628 | Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents(PECATI) | completed | Phase 2 | 43 | MedSIROTHER | 3 | Feb 19, 2026 | clinicaltrials |
| NCT01621568 | Sunitinib for Advanced Thymus Cancer Following Earlier Treatment | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2024 | clinicaltrials |
| NCT00010257 |
| Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma |
| completed |
| Phase 2 |
| 46 |
| Eastern Cooperative Oncology GroupNETWORK |
| 1 |
| Jun 29, 2023 |
| clinicaltrials |
| NCT00003283 | Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma | completed | Phase 2 | 38 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 15, 2023 | clinicaltrials |
| NCT02049047 | Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy(ONC-2010-001) | completed | Phase 2 | 41 | Armando Santoro, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02220855 | A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas | completed | Phase 2 | 14 | Patrick Joseph Loehrer Sr.OTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT00198133 | Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma | completed | Phase 2 | 27 | Patrick Joseph Loehrer Sr.OTHER | 1 | Jul 22, 2019 | clinicaltrials |
| NCT01364727 | A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies | completed | Phase 2 | 33 | Heather WakeleeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00332969 | Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma | completed | Phase 2 | 25 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00965250 | Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2016 | clinicaltrials |
| NCT00589290 | Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT00387868 | Preoperative Treatment of Patients With High Risk Thymoma | completed | Phase 2 | 21 | Valley Health SystemOTHER | 2 | Dec 9, 2014 | clinicaltrials |
| NCT00369889 | A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer | completed | Phase 2 | 18 | Indiana UniversityOTHER | 1 | Jun 3, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Feb 19, 2026source: clinicaltrials